↓ Skip to main content

Spotlight on Atomoxetine in Adults with Attention-Deficit Hyperactivity Disorder

Overview of attention for article published in CNS Drugs, August 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (75th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

policy
1 policy source
wikipedia
7 Wikipedia pages

Citations

dimensions_citation
40 Dimensions

Readers on

mendeley
43 Mendeley
citeulike
1 CiteULike
connotea
2 Connotea
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Spotlight on Atomoxetine in Adults with Attention-Deficit Hyperactivity Disorder
Published in
CNS Drugs, August 2012
DOI 10.2165/00023210-200418060-00011
Pubmed ID
Authors

Dene Simpson, Greg L. Plosker

Abstract

Atomoxetine (Strattera) is a selective noradrenaline (norepinephrine) reuptake inhibitor and nonstimulant that has shown greater efficacy than placebo in attention-deficit hyperactivity disorder (ADHD) in adults. In two large, well controlled, 10-week trials in adults with ADHD, improvements in ADHD symptoms, as assessed by investigator- and patient-rated scores, were greater with oral atomoxetine (60, 90 or 120 mg/day) than with placebo. Mean reductions in the total ADHD symptom score on the investigator-rated Conners' Adult ADHD Rating Scale (CAARS) in atomoxetine versus placebo recipients were 28.3% versus 18.1% and 30.1% versus 19.6%, respectively. Mean reductions in the scores on the Clinician Global Impression of Severity Scale, patient-rated CAARS and Wender-Reimherr Adult Attention Deficit Disorder Scale were also significantly greater with atomoxetine than with placebo. Continued efficacy was demonstrated in a noncomparative, 34-week extension phase. Atomoxetine was generally well tolerated in clinical trials; withdrawal rates due to adverse events in atomoxetine- versus placebo-treated patients participating in the two major trials were 7.8% versus 4.3% and 9.3% versus 2.4% (p < 0.05 for the latter trial). Adverse events reported significantly more frequently with atomoxetine than placebo included dry mouth, insomnia, nausea, decreased appetite, constipation, dizziness, sweating, dysuria, sexual problems and palpitations. Modest increases in heart rate and blood pressure were well tolerated and gradually decreased on cessation of treatment. Atomoxetine was not associated with QT interval prolongation. Atomoxetine can be administered once or twice daily. Its subjective-effects profile is different to that of methylphenidate and atomoxetine is not associated with abuse or diversion; it is therefore not a controlled substance in the US. This also means repeat prescriptions during long-term treatment can be more conveniently processed.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Puerto Rico 1 2%
Unknown 41 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 19%
Student > Master 6 14%
Researcher 5 12%
Student > Doctoral Student 4 9%
Student > Bachelor 4 9%
Other 7 16%
Unknown 9 21%
Readers by discipline Count As %
Medicine and Dentistry 12 28%
Psychology 5 12%
Neuroscience 3 7%
Agricultural and Biological Sciences 3 7%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Other 6 14%
Unknown 12 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 November 2023.
All research outputs
#5,447,195
of 25,374,917 outputs
Outputs from CNS Drugs
#512
of 1,388 outputs
Outputs of similar age
#38,821
of 187,955 outputs
Outputs of similar age from CNS Drugs
#164
of 541 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,388 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,955 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 541 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.